1.
|
Phase: Phase IV, Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: GPOH-NB2004, EU-20661, NCT00410631
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: RET5, NCT00186888
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 21
Sponsor: Other
Protocol IDs: CCLG-EPSSG-RMS-2005, EU-20639, EUDRACT-2005-000217-35, UKCCSG-RMS-2005, NCT00379457
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 3104000, NCT00437307
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 12 and under
Sponsor: NCI
Protocol IDs: COG-ANBL0531, ANBL0531, NCT00499616
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KTN32313R, NCT00477282
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 006/027/ICI, NCT00532818
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 006/028/DDI, NCT00533299
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMR PH GL 2007 CL 001, NCT00547651
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-0240, GOG-0240, NCT00803062
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DOLG7, NCT00812266
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22224, 2009-011400-33, NCT00976911
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CT/06.14, NCT00429559
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 120
Sponsor: Other
Protocol IDs: R01 CA 89395-01, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-07082, 07-082, 7937, NCT00521144
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GYN06-111, NCT00526799
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MCC-12733, NCT00325416
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ARCAGY-GINECO-CE102, GINECO CE102, ARCAGY-HYCAR, INCA-RECF0757, EUDRACT-2008-001842-19, NCT00807079
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 month and over
Sponsor: Other
Protocol IDs: RTB1, NCT00901238
|
|
20.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0861, MC0861, 8329, NCT01012817
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DAN-104864/373, DAN-104864-A/373, EU-98052, SB-104864-A/373, SB-104864/373, NCT00003732
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BCM-H-16155, NCT00109798
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAR\TAXHY, NCT00189566
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCI 03-33, NCT00257816
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYU-0367, 6317, NCI-6317, NCT00313612
|
